Obel Niels, Fox Matthew P, Tetens Malte M, Pedersen Lars, Krause Tyra Grove, Ullum Henrik, Sørensen Henrik Toft
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, 2300, Denmark.
Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, 2100, Denmark.
Clin Epidemiol. 2024 Jul 25;16:501-512. doi: 10.2147/CLEP.S468572. eCollection 2024.
Observational studies of SARS-CoV-2 vaccine effectiveness are prone to confounding, which can be illustrated using negative control methods.
Nationwide population-based cohort study including two cohorts of Danish residents 60-90 years of age matched 1:1 on age and sex: A vaccinated and a non-vaccinated cohort, including 61052 SARS-CoV-2 vaccinated individuals between 1 March and 1 July 2021 and 61052 individuals not vaccinated preceding 1 July 2021. From these two cohorts, we constructed negative control cohorts of individuals diagnosed with SARS-CoV-2 infection or acute myocardial infarction, stroke, cancer, low energy fracture, or head-trauma. Outcomes were SARS-CoV-2 infection, negative control outcomes (eg, mammography, prostate biopsy, operation for cataract, malignant melanoma, examination of eye and ear), and death. We used Cox regression to calculate adjusted incidence and mortality rate ratios (aIRR and aMRR).
Risks of SARS-CoV2 infection and all negative control outcomes were elevated in the vaccinated population, ranging from an aIRR of 1.15 (95% CI: 1.09-1.21) for eye examinations to 3.05 (95% CI: 2.24-4.14) for malignant melanoma. Conversely, the risk of death in the SARS-CoV-2 infected cohort and in all negative control cohorts was lower in vaccinated individuals, ranging from an aMRR of 0.23 (95% CI: 0.19-0.26) after SARS-CoV-2 infection to 0.50 (95% CI: 0.37-0.67) after stroke.
Our findings indicate that observational studies of SARS-CoV-2 vaccine effectiveness may be subject to substantial confounding. Therefore, randomized trials are essential to establish vaccine efficacy after the emergence of new SARS-CoV-2 variants and the rollout of multiple booster vaccines.
对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗有效性的观察性研究容易受到混杂因素的影响,这可以通过阴性对照方法来说明。
基于全国人口的队列研究,包括两组年龄在60 - 90岁之间的丹麦居民,按年龄和性别1:1匹配:一组接种疫苗组和一组未接种疫苗组,包括2021年3月1日至7月1日期间61052名接种SARS-CoV-2疫苗的个体以及2021年7月1日前未接种疫苗的61052名个体。从这两组中,我们构建了被诊断为SARS-CoV-2感染、急性心肌梗死、中风、癌症、低能量骨折或头部创伤的个体的阴性对照队列。结局包括SARS-CoV-2感染、阴性对照结局(如乳房X线摄影、前列腺活检、白内障手术、恶性黑色素瘤、眼耳检查)和死亡。我们使用Cox回归来计算调整后的发病率和死亡率比值(aIRR和aMRR)。
接种疫苗人群中SARS-CoV-2感染和所有阴性对照结局的风险均升高,眼检查的aIRR为1.15(95%置信区间:1.09 - 1.21),恶性黑色素瘤的aIRR为3.05(95%置信区间:2.24 - 4.14)。相反,接种疫苗个体中SARS-CoV-2感染队列和所有阴性对照队列中的死亡风险较低,SARS-CoV-2感染后的aMRR为0.23(95%置信区间:0.19 - 0.26),中风后的aMRR为0.50(95%置信区间:0.37 - 0.67)。
我们的研究结果表明,对SARS-CoV-2疫苗有效性的观察性研究可能存在大量混杂因素。因此,在新的SARS-CoV-2变异株出现和多种加强疫苗推出后,随机试验对于确定疫苗效力至关重要。